Professional Documents
Culture Documents
The Nobel Prize in Physiology or Medicine, administered by the Nobel Foundation, is awarded
once a year for outstanding discoveries in the fields of life sciences and medicine. It is one of the
five Nobel Prizes established in 1895 by Swedish chemist Alfred Nobel, the inventor of dynamite,
in his will.
What has Nobel Prize in Physiology or Medicine to do with the life science industry? We may find
an answer from the Prize awarded in the past decade.
The Nobel Prize in Physiology or Medicine 2014 was awarded to three scientists from the
United States and Norway, John O'Keefe, May-Britt Moser and Edward Moser, for "discovering
cells that make up the brain's positioning system." They found that the circuit formed by the rat
hippocampus constitutes a wide range of localization systems in the brain - the brain's GPS. This
research has promoted the progress of brain imaging system and the treatment of neurological
diseases, such as Alzheimer's disease. It provides a new way to understand cognitive processes
such as memory, thinking and planning.
The Nobel Prize in Physiology or Medicine 2013 was awarded to American scientists James E.
Rothman, Randy W. Schekman and German scientist Thomas C. Südhof, in recognition of their
discovery of intracellular vesicular trafficking regulation mechanism. The study revealed how
cellular cargo around "vesicles" can be transported to the correct cellular targets at the right time.
Without the precise and wonderful organization of vesicles, the cells will get in turmoil and defect
in their vesicles transportation, leading to these diseases. At present, the study is applied to the
pathophysiology of diseases such as nervous system diseases, diabetes and immune diseases.
The Nobel Prize in Physiology or Medicine 2012 was presented to British scientist Sir John B.
Gurdon and Japanese medical professor Shinya Yamanaka in recognition of their revolutionary
contributions in the field of somatic cell reprogramming technology. Shinya Yamanaka used gene
technology to successfully induce pluripotent stem cells that have the ability to differentiate by
reprogramming mouse mature cells. The value of this technology lies in the establishment of
patient-specific long-term stable cell lines for individualized drug screening and the use of stem
cells obtained from the somatic cells of patients as a material for cell therapy in disease modeling,
drug screening and cell therapy. The huge application prospect is regarded as the new hope for cell
therapy.
About Author
https://medium.com/@candyjkswift/part-ii-the-industrialization-of-nobel-prize-in-physiology-or-
medicine-in-the-past-decade-46f93ab0cdaa